Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
136 USD | -1.28% | +3.02% | +3.21% |
Financials (USD)
Sales 2024 * | 2.21B | Sales 2025 * | 2.52B | Capitalization | 13.86B |
---|---|---|---|---|---|
Net income 2024 * | 490M | Net income 2025 * | 666M | EV / Sales 2024 * | 5.32 x |
Net cash position 2024 * | 2.09B | Net cash position 2025 * | 2.88B | EV / Sales 2025 * | 4.36 x |
P/E ratio 2024 * |
29.2
x | P/E ratio 2025 * |
21.6
x | Employees | 1,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | -0.87% | ||
1 week | +3.94% | ||
Current month | -0.12% | ||
1 month | -1.78% | ||
3 months | -2.30% | ||
6 months | +27.28% | ||
Current year | +4.55% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 215 M€ | +12.27% | - | |
3.81% | 1 M€ | 0.00% | - | |
1.85% | 8 M€ | 0.00% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 136 | -1.28% | 709 152 |
24-04-25 | 137.8 | -0.87% | 735,781 |
24-04-24 | 139 | -0.80% | 927,988 |
24-04-23 | 140.1 | +4.81% | 1,607,818 |
24-04-22 | 133.7 | +1.26% | 575,067 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.55% | 13.86B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.79% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+32.11% | 12.04B | |
-26.18% | 8.08B |
- Stock Market
- Equities
- NBIX Stock